Abstract 299P
Background
With the increasing proportion of women surviving carcinoma cervix, quality of life becomes an important issue. Most of the diagnosed women belong to the sexually active group (mean age 50 years). Therefore impact on sexual health is vital. Since there are only few studies on the topic, this study is to assess sexual dysfunction issues in patients treated with multimodality therapy using the LENT SOMA scores.
Methods
The study was prospective. A total of 85 patients were accrued comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. Sixty six patients were treated with radiotherapy in which 46 patients received chemoradiotherapy and 19 had surgery prior to postoperative radiotherapy. The mean age was 47.81 years with a range of 2568 years. Completion of LENT SOMA scale and Statistical analysis for sexual dysfunction scores was done- stage wise and treatment wise.
Results
Mean subjective sexual function and satisfaction scores was highest in stage IIIA disease (0.0972) while maximum subjective sexual score was seen in stage IIB disease (0.94). Mean objective score VG (Vagina) was highest in stage IVA and maximum score (0.80) was seen in stage IIIB. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients in which gap between treatment and interview was 11 years and maximum score was highest (0.94) in same group. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients who were treated in earlier years when compared with other patients p value-0.093). Sexual function and satisfaction maximum score was highest in combined surgery and radiotherapy group (0.94) and minimum in RT alone group (0.54). The objective mean score VG (Vagina) was highest in combined surgery and radiotherapy group and maximum score(0.80) was highest in the radiotherapy(+chemo) group.
Conclusions
Currently there is no single self-report measure in routine clinical follow use which is easy to complete and incorporates all aspects of sexual health for people affected by cancer. We used LENT SOMA scale in our study, it provides a comprehensive system to assess treatment induced sexual difficulties to score the impact of radiotherapy morbidity in cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
111P - Comparison of the efficacy and safety of fruquintinib and fruquintinib combined with immune checkpoint inhibitors in the treatment of metastatic microsatellite stable colorectal cancer: A real-world study
Presenter: Zhiqiang Wang
Session: Poster Display
Resources:
Abstract
112P - Optimal classification and treatment strategy based on technical and oncological futures in recurrence of colorectal liver metastases
Presenter: Kosuke Kobayashi
Session: Poster Display
Resources:
Abstract
113P - Phase I/II study of capecitabine(C)/oxaliplatin(O)/irinotecan(I) combined with bevacizumab(B) in the first-line treatment of metastatic colorectal cancer (mCRC)
Presenter: Kai Ou
Session: Poster Display
Resources:
Abstract
114P - The prognostic role of LAG-3 expression in metastatic colorectal cancer
Presenter: Yi-Hsuan Huang
Session: Poster Display
Resources:
Abstract
115P - Sidedness and survival of chemo-refractory metastatic colorectal cancer treated with lonsurf or regorafenib: A nationwide population-based study in Taiwan
Presenter: Meng-Che Hsieh
Session: Poster Display
Resources:
Abstract
116P - Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis
Presenter: Monika Chhayani
Session: Poster Display
Resources:
Abstract
117P - Australasian real-world treatment selection and clinical outcomes for patients with left side (LS), RAS wildtype (RASwt) metastatic colorectal cancer (mCRC)
Presenter: Vanessa Wong
Session: Poster Display
Resources:
Abstract
119P - Neoadjuvant chemoradiotherapy in the mode of hypofractionation in locally advanced rectal cancer: Is it time to change standards of care?
Presenter: Abror Abdujapparov
Session: Poster Display
Resources:
Abstract
120P - Improved clinical outcomes with cetuximab maintenance therapy in left-sided RAS/BRAF wild-type metastatic colorectal cancer: A real-world study of Hunan cancer hospital
Presenter: Xiaolin Yang
Session: Poster Display
Resources:
Abstract
121P - Single-cell sequencing reveals the role of Treg cells with high expression of BIRC3 in regulating the progression of colorectal cancer
Presenter: Yuqiu Xu
Session: Poster Display
Resources:
Abstract